大禹生物
(920970)
| 流通市值：3.92亿 | | | 总市值：6.20亿 |
| 流通股本：7007.13万 | | | 总股本：1.11亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 136,198,629.41 | 71,914,063.08 | 33,740,362.7 | 167,480,613.05 |
| 营业收入 | 136,198,629.41 | 71,914,063.08 | 33,740,362.7 | 167,480,613.05 |
| 二、营业总成本 | 157,761,377.75 | 84,319,961.11 | 38,871,433.38 | 199,734,100.78 |
| 营业成本 | 126,248,406.36 | 62,736,326.52 | 29,152,163.14 | 154,050,474.58 |
| 税金及附加 | 1,549,212.13 | 1,296,707.2 | 120,217.25 | 2,653,220.9 |
| 销售费用 | 8,515,790.43 | 5,742,221.99 | 2,682,092.82 | 12,982,821.89 |
| 管理费用 | 13,596,156.5 | 9,400,297.73 | 4,600,096.6 | 19,780,851.69 |
| 研发费用 | 3,883,945.56 | 2,623,272.88 | 1,264,383.24 | 6,800,764.61 |
| 财务费用 | 3,967,866.77 | 2,521,134.79 | 1,052,480.33 | 3,465,967.11 |
| 其中:利息费用 | 3,903,615.32 | 2,485,091.57 | 1,036,055.7 | 3,438,058.22 |
| 其中:利息收入 | 9,750.4 | 8,289.28 | 5,086.65 | 31,864.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -2,360 |
| 加:投资收益 | -1,121.84 | -253.34 | - | 22,743.28 |
| 资产处置收益 | -917,463.61 | 31,078.81 | 27,337.6 | - |
| 资产减值损失(新) | -18,406,493.37 | -15,832,943.01 | -13,562,884.6 | -2,540,919.07 |
| 信用减值损失(新) | -1,345,543.33 | -1,063,614.48 | -339,765.88 | -859,716.69 |
| 其他收益 | 4,650,065.08 | 2,721,766.91 | 1,589,493.43 | 5,930,948.27 |
| 四、营业利润 | -37,583,305.41 | -26,549,863.14 | -17,416,890.13 | -29,702,791.94 |
| 加:营业外收入 | 255.25 | 253.84 | 253.24 | 420.07 |
| 减:营业外支出 | 4,002.63 | - | - | 121,438.04 |
| 五、利润总额 | -37,587,052.79 | -26,549,609.3 | -17,416,636.89 | -29,823,809.91 |
| 减:所得税费用 | - | - | - | 29,371.17 |
| 六、净利润 | -37,587,052.79 | -26,549,609.3 | -17,416,636.89 | -29,853,181.08 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -37,587,052.79 | -26,549,609.3 | -17,416,636.89 | -29,853,181.08 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -37,587,052.79 | -26,549,609.3 | -17,416,636.89 | -29,853,181.08 |
| 扣除非经常损益后的净利润 | -41,441,882.05 | -29,515,393.01 | -19,195,493.71 | -35,716,594.06 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.34 | -0.24 | -0.16 | -0.27 |
| (二)稀释每股收益 | -0.34 | -0.24 | -0.16 | -0.27 |
| 八、其他综合收益 | 2,626,320 | -6,880 | - | - |
| 归属于母公司股东的其他综合收益 | 2,626,320 | -6,880 | - | - |
| 九、综合收益总额 | -34,960,732.79 | -26,556,489.3 | -17,416,636.89 | -29,853,181.08 |
| 归属于母公司股东的综合收益总额 | -34,960,732.79 | -26,556,489.3 | -17,416,636.89 | -29,853,181.08 |
| 公告日期 | 2026-10-26 | 2026-08-24 | 2026-04-27 | 2026-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |